Vrije Universiteit Brussel

Matthias D'Huyvetter

Nick Devoogdt

Tony Lahoutte

Jens De Vos

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a γ-emitter and β-emitter.

Radiolabelled antibody fragments for use in treating cancer

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a &#x3b3;-emitter and &#x3b2;-emitter.

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V) or functional fragments thereof, wherein said Vor functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.

Growing community of inventors

Antwerp, Belgium

Matthias D'Huyvetter